Study Objectives: Below the knee venous thromboembolism (VTE) present difficult decisions for emergency physicians as risks associated with anticoagulation may outweighs the low risk of propagation of clot. Our hypothesis was patients with below the knee deep venous thrombosis (DVT) treated who were compliant with outpatient therapy would have a lower relative risk of propagation and recurrence than noncompliant patients.
Methods: This was a pre-planned secondary analysis of a protocol for low risk outpatient treatment of any VTE using the target specific anticoagulant, rivaroxaban, for outpatient treatment. Inclusion criteria were any patient with an acute isolated below the knee VTE found on duplex doppler ultrasound interpreted via radiologist. Below the knee DVT were defined as posterior tibial, gastroc, and peroneal veins. Compliance was defined as taking medication as prescribed daily for a full 12 weeks, and was done through a series of questions at follow-up. Propagation was defined as any extension of a below the knee DVT to proximal clot (popliteal and above). Recurrence was assessed at 1 yr post treatment through a state wide patient database. Patients who were lost to follow-up were considered non-compliant. Bleeding complications was defined in accordance with ISTH definition of major bleeding. Relative risk was calculated for propagation, recurrence, and bleeding with 95% CI.
Results: 279 patients were diagnosed with DVT and treated with an ODXa inhibitor from 3/25/2013-12/31/2017, of these 67 of these were below the knee DVT. Forty-five patients were compliant with medication therapy. Three patients who were non-compliant developed propagation while no patient on therapy developed propagation. Only one patient had a recurrence of DVT within a year. The relative risk for propagation in compliant patients was 0.07 (95% CI 0.04-1.26) (p¼0.07), with a NNT of 7 to prevent propagation. One non-compliant patient had a reccurence. No patient had a major bleeding event. Four compliant patients had bleeding complications which were: GI bleed (2), bleeding after temporal biopsy (1), bleeding from external hemorrhoids (1). One non-compliant patient had epistaxis and stopped therapy themselves. The relative risk of recurrence (p¼0.25) and bleeding (p¼0.56) did not reach significance.
Conclusions: In this single center study of 66 patients, isolated below the knee DVT had a trend toward a lower risk of propagation to proximal DVT without having any major significant bleeding risk. Teams (PERTs); describing the frequency of team activation, patient characteristics, pulmonary embolism (PE) severity, treatments delivered and outcomes.
Methods: We enrolled all patients from the National PERT Consortium multicenter registry with a PERT activation between October 18, 2016 to October 17, 2017. Data is presented combined and by PERT institutions (with 40 activations). Analyses of PE severity, treatment and outcomes were limited to patients with confirmed PE. 30-day follow-up analyses were limited to subjects for whom follow-up was complete.
Results: In the year of inclusion there were 475 unique PERT activations with acute PE confirmed in 416 (87.6%). The number of activations at each institution ranged from 3 to 13 activations/month/1000 beds with the majority originating from the emergency department (281/475; 59.3%). Figure 1 shows the distribution of patients with confirmed PE according to the European Society of Cardiology risk stratification guidelines. Overall, we found most patients warranting a PERT activation to be at intermediate-low and intermediate-high risk of early mortality. Across institutions, the proportion of patients at low risk ranged from 2.4% to 25.8% while the proportion of highrisk patients ranged from 5.6% to 24.4%. Anticoagulation alone was the most common therapy, delivered to 289/416 (69.5%) of patients with confirmed PE. The overall proportion of patients receiving advanced therapy ranged from 18.7% to 48.6% between institutions. Figure 1 shows the proportions of patients receiving anticoagulation alone versus any advanced therapy stratified by PE risk group. Thirty-day mortality was 15.7% overall, but ranged between institutions from 9.1% to 44.4%.
Conclusions: The frequency of team activation, PE severity, treatments delivered and 30-day mortality varies between 8 US PERTs from the National PERT Consortium TM multicenter registry. Study Objectives: Cerebral oximetry is a portable, non-invasive monitoring system that uses near-infrared spectroscopy (NIRS) to provide continuous, real-time measurements of regional cerebral oxygenation saturation levels (rSo 2 ). We often use other surrogate markers thought to be predictive of severe adverse events such as capnography, pulse oximetry, and supportive airway measures, but the validity of these parameters to accurately reflect vital end-organ oxygenation and procedural risk remain unclear. The primary objective of this study is to evaluate the effect of adult procedural sedation on rSo2 levels. The secondary objective is to assess whether respiratory depression and supportive airway measures occurring during procedural sedation are associated with decreases in rSo2.
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Methods: We performed a prospective observational pilot study on adult patients (>18 years) undergoing procedural sedation in the emergency department (ED). An adhesive sensor was placed unilaterally on the forehead of each patient for rSo2
